T1	Participants 129 188	advanced gastric or gastroesophageal cancer adenocarcinoma:
T2	Participants 225 290	patients with advanced gastric or gastroesophageal cancer (AGGEC)
T3	Participants 512 557	In a multinational trial (V325), 445 patients